Nicola Valeri

List of Publications by Year
in descending order

87 papers	6,565 citations	109321 35 h-index	66911 78 g-index
90 all docs	90 docs citations	90 times ranked	11523 citing authors

#	Article	IF	Citations
1	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018, 359, 920-926.	12.6	1,199
2	Mismatch Repair Deficiency, Microsatellite Instability, and Survival. JAMA Oncology, 2017, 3, 1197.	7.1	398
3	MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 21098-21103.	7.1	333
4	Modulation of mismatch repair and genomic stability by miR-155. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6982-6987.	7.1	306
5	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. Journal of Clinical Oncology, 2019, 37, 3392-3400.	1.6	293
6	MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer. Cancer Cell, 2014, 25, 469-483.	16.8	267
7	Association of a MicroRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia. JAMA - Journal of the American Medical Association, 2011, 305, 59.	7.4	256
8	Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. Journal of Clinical Oncology, 2016, 34, 2721-2727.	1.6	214
9	Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 786-791.	7.1	207
10	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. Cancer Discovery, 2018, 8, 1270-1285.	9.4	187
11	MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside. Targeted Oncology, 2020, 15, 261-278.	3.6	183
12	MicroRNAs in the Pathogenesis of Cancer. Seminars in Oncology, 2011, 38, 724-733.	2.2	181
13	Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cellular and Molecular Life Sciences, 2018, 75, 4151-4162.	5.4	150
14	Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy. Nature Communications, 2021, 12, 366.	12.8	138
15	An evaluation and replication of mi<scp>RNA</scp>s with disease stage and colorectal cancerâ€specific mortality. International Journal of Cancer, 2015, 137, 428-438.	5.1	119
16	Hepatitis C Virus Proteins Modulate MicroRNA Expression and Chemosensitivity in Malignant Hepatocytes. Clinical Cancer Research, 2010, 16, 957-966.	7.0	108
17	MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology, 2018, 154, 1066-1079.e5.	1.3	94
18	Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mammalian Genome, 2009, 20, 573-80.	2.2	91

#	Article	IF	Citations
19	rs4919510 in hsa-mir-608 Is Associated with Outcome but Not Risk of Colorectal Cancer. PLoS ONE, 2012, 7, e36306.	2.5	85
20	Exploiting evolutionary steering to induce collateral drug sensitivity in cancer. Nature Communications, 2020, 11, 1923.	12.8	79
21	Comprehensive miRNA profiling of surgically staged endometrial cancer. American Journal of Obstetrics and Gynecology, 2010, 202, 656.e1-656.e8.	1.3	77
22	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. Oncologist, 2020, 25, 481-487.	3.7	77
23	Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut, 2017, 66, 1268-1277.	12.1	75
24	A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials, 2017, 18, 394.	1.6	72
25	A MYCâ€“GCN2â€“eIF2Î± negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer. Nature Cell Biology, 2019, 21, 1413-1424.	10.3	65
26	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. Gut, 2018, 67, 1484-1492.	12.1	59
27	c-Src drives intestinal regeneration and transformation. EMBO Journal, 2014, 33, 1474-91.	7.8	56
28	Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. Frontiers in Oncology, 2018, 8, 226.	2.8	56
29	KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Scientific Reports, 2018, 8, 1445.	3.3	55
30	Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. British Journal of Cancer, 2019, 121, 257-263.	6.4	53
31	Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. Critical Reviews in Oncology/Hematology, 2019, 143, 153-163.	4.4	49
32	Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Modern Pathology, 2012, 25, 1333-1344.	5.5	48
33	Characterisation of the immune-related transcriptome in resected biliary tract cancers. European Journal of Cancer, 2017, 86, 158-165.	2.8	47
34	MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression. Cancer Discovery, 2021, 11, 1228-1247.	9.4	45
35	miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. Clinical Cancer Research, 2019, 25, 3830-3838.	7.0	42
36	LONG-NONCODING RNAs in gastroesophageal cancers. Non-coding RNA Research, 2018, 3, 195-212.	4.6	39

#	Article	IF	Citations
37	Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis. Oncotarget, 2014, 5, 7162-7171.	1.8	35
38	The molecular landscape of colitis-associated carcinogenesis. Digestive and Liver Disease, 2017, 49, 326-330.	0.9	34
39	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 280-284.	2.3	33
40	MicroRNAs and genomic variations: from Proteus tricks to Prometheus gift. Carcinogenesis, 2009, 30, 912-917.	2.8	31
41	Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy â€“ results from the <scp>MRC OE</scp>02 oesophageal cancer trial. Histopathology, 2018, 72, 1180-1188.	2.9	31
42	Modulation of Biliary Cancer Chemoâ€Resistance Through MicroRNAâ€Mediated Rewiring of the Expansion of CD133+ Cells. Hepatology, 2020, 72, 982-996.	7.3	30
43	DNA methylation of shelf, shore and open sea CpG positions distinguish high microsatellite instability from low or stable microsatellite status colon cancer stem cells. Epigenomics, 2019, 11, 587-604.	2.1	29
44	Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. Oncogene, 2019, 38, 1717-1733.	5.9	29
45	MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. British Journal of Cancer, 2016, 115, 1343-1350.	6.4	27
46	An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer. Cancer Epidemiology, 2014, 38, 583-590.	1.9	26
47	Vault RNAs: hidden gems in RNA and protein regulation. Cellular and Molecular Life Sciences, 2021, 78, 1487-1499.	5.4	26
48	Let-7c down-regulation in Helicobacter pylori-related gastric carcinogenesis. Oncotarget, 2016, 7, 4915-4924.	1.8	26
49	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Annals of Oncology, 2015, 26, 1936-1941.	1.2	24
50	EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. Gut, 2021, 70, 1632-1641.	12.1	24
51	Early miR-223 Upregulation in Gastroesophageal Carcinogenesis. American Journal of Clinical Pathology, 2017, 147, 301-308.	0.7	23
52	Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. Genes, 2021, 12, 33.	2.4	23
53	Pathogenetic and clinical relevance of microRNAs in colorectal cancer. Cancer Genomics and Proteomics, 2009, 6, 195-204.	2.0	22
54	A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. Cancers, 2020, 12, 2452.	3.7	20

#	Article	IF	Citations
55	MicroRNAs as mediators of drug resistance mechanisms. Current Opinion in Pharmacology, 2020, 54, 44-50.	3.5	19
56	Nutlin-3 Downregulates the Expression of the Oncogene TCL1 in Primary B Chronic Lymphocytic Leukemic Cells. Clinical Cancer Research, 2011, 17, 5649-5655.	7.0	17
57	Circulating microRNA expression profiling revealed miR-92a-3p as a novel biomarker of Barrettâ€™s carcinogenesis. Pathology Research and Practice, 2020, 216, 152907.	2.3	17
58	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. Carcinogenesis, 2016, 37, 852-857.	2.8	15
59	Streamlining Detection of Fusion Genes in Colorectal Cancer: Having â€œFaithâ€•in Precision Oncology in the (Tissue) â€œAgnosticâ€•Era. Cancer Research, 2019, 79, 1041-1043.	0.9	15
60	miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. Translational Oncology, 2019, 12, 282-291.	3.7	14
61	Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. Haematologica, 2018, 103, 2049-2058.	3.5	13
62	MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. Cell Death and Differentiation, 2021, 28, 2970-2982.	11.2	13
63	From Barrett metaplasia to esophageal adenocarcinoma: the molecular background. Histology and Histopathology, 2016, 31, 25-32.	0.7	13
64	Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. Clinical Cancer Research, 2017, 23, 7543-7549.	7.0	12
65	HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 159-171.	2.0	10
66	Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. European Journal of Surgical Oncology, 2019, 45, 1479-1482.	1.0	10
67	Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. Clinical Colorectal Cancer, 2019, 18, 64-71.e1.	2.3	10
68	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 2021, 12, 6738.	12.8	10
69	Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patientsâ€™ Prognosis. International Journal of Surgical Pathology, 2019, 27, 816-835.	0.8	8
70	Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. Cancer Cell International, 2018, 18, 131.	4.1	7
71	Class(y) Dissection of BRAF Heterogeneity: Beyond Non-V600. Clinical Cancer Research, 2019, 25, 6896-6898.	7.0	7
72	Circulating Tumour DNAs and Non-Coding RNAs as Liquid Biopsies for the Management of Colorectal Cancer Patients. Gastrointestinal Disorders, 2020, 2, 212-235.	0.8	7

#	Article	IF	Citations
73	Combining Molecularly Targeted Agents: Is More Always Better?. Clinical Cancer Research, 2017, 23, 1123-1125.	7.0	6
74	First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. Oncotarget, 2017, 8, 111795-111806.	1.8	6
75	R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. Annals of Hematology, 2020, 99, 105-112.	1.8	6
76	Translational research and application of basic biology to clinical trial development in GI cancers. Annals of Translational Medicine, 2018, 6, 164-164.	1.7	6
77	MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours. Targeted Oncology, 2018, 13, 423-436.	3.6	5
78	Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling. Frontiers in Endocrinology, 2022, 13, 834075.	3.5	5
79	DCE-MRI is more sensitive than IVIM-DWI for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases. Cancer Imaging, 2021, 21, 67.	2.8	4
80	Challenges and perspectives for immunotherapy inÂoesophageal cancer: A look to the future (Review). International Journal of Molecular Medicine, 2021, 47, .	4.0	3
81	Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. Frontiers in Oncology, 2020, 10, 1634.	2.8	2
82	A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer. Cellular Oncology (Dordrecht), 2021, 44, 1197-1206.	4.4	2
83	Anti-miR-135b in colon cancer treatment: Results from a preclinical study.. Journal of Clinical Oncology, 2012, 30, 457-457.	1.6	2
84	Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinoma. The Lancet Gastroenterology and Hepatology, 2021, 6, 515-516.	8.1	1
85	Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer. Clinical Cancer Research, 2021, 27, 2964-2966.	7.0	0
86	Abstract 4086: Ultraconserved non-coding RNAs are involved in human hepatocellular cancer growth. , 2010, , .		0
87	Abstract 1178: Involvement of MEG3, a long non-coding RNA, in hepatocellular cancer (HCC). , 2011, , .		0